This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GHDX Genomic Health (GHDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Genomic Health Stock (NASDAQ:GHDX) 30 days 90 days 365 days Advanced Chart Get Genomic Health alerts:Sign Up Key Stats Today's Range$63.44▼$63.4450-Day Range$63.44▼$69.7952-Week Range$50.77▼$90.18VolumeN/AAverage Volume1.05 million shsMarket Capitalization$2.38 billionP/E Ratio60.42Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California. Read More Receive GHDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genomic Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GHDX Stock News HeadlinesPanGenomic Health Unveils AI Platform and Accelerates Warrant ExpirationJuly 25, 2025 | tipranks.comPanGenomic Health Announces Leadership Changes and Financial UpdatesJuly 11, 2025 | tipranks.comTrump Did What!?Last May, President Trump signed four executive orders that could spark the biggest energy disruption in decades. This move opens the door for a next-gen power source with the potential to upend oil and gas, slash emissions, and accelerate artificial intelligence breakthroughs. While stocks tied to this trend have already soared, one overlooked corner of the industry could deliver even bigger gains—and it’s still flying under the radar. | Stansberry Research (Ad)PanGenomic Health Releases 2024 Financial ResultsJuly 2, 2025 | tipranks.comPanGenomic Health Enhances Investor Relations and Updates Warrant ExpirationJune 23, 2025 | tipranks.comPanGenomic Health Updates on Cease Trade Order and Financial FilingsMay 22, 2025 | tipranks.comPanGenomic Health Announces CFO TransitionApril 4, 2025 | tipranks.comPanGenomic Health Reprices Warrants to Enhance Market AppealJanuary 29, 2025 | tipranks.comSee More Headlines GHDX Stock Analysis - Frequently Asked Questions How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) released its quarterly earnings results on Monday, November, 11th. The medical research company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.37 by $0.11. Genomic Health had a trailing twelve-month return on equity of 19.62% and a net margin of 12.81%. What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genomic Health investors own include Revance Therapeutics (RVNC), Horizon Therapeutics Public (HZNP), Illumina (ILMN), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX) and Exelixis (EXEL). Company Calendar Last Earnings11/11/2019Today8/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:GHDX CIK1131324 Webwww.genomichealth.com Phone650-556-9300FaxN/AEmployees829Year FoundedN/AProfitability EPS (Trailing Twelve Months)$1.05 Trailing P/E Ratio60.42 Forward P/E Ratio40.15 P/E GrowthN/ANet Income$25.68 million Net Margins12.81% Pretax MarginN/A Return on Equity19.62% Return on Assets14.89% Debt Debt-to-Equity Ratio0.15 Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$394.11 million Price / Sales6.05 Cash Flow$1.45 per share Price / Cash Flow43.76 Book Value$7.48 per share Price / Book8.48Miscellaneous Outstanding Shares37,590,000Free FloatN/AMarket Cap$2.38 billion OptionableOptionable Beta0.90 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:GHDX) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genomic Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genomic Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.